Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122691 · ClinicalTrials.gov registry record · Phase 1
Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03122691: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT03122691 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122691, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This research is being done to measure the effects of both oral and vaporized cannabis (marijuana), at different doses, on the ability to perform certain tasks such as balancing, eye tracking, and computerized measures of memory and attention, as well as performance on a novel app (DRUID) that is being developed for field sobriety testing. The investigators will collect biological fluids (urine, blood, saliva/spit) after cannabis is eaten or vaporized to see if there are markers in those fluids that can predict performance on the behavioral tasks and the DRUID App. The results of this study will help us better understand the effects of using cannabis, and to help identify behaviors and/or substances in the body that relate to cannabis impairment.
Interventions
- DRUG cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122691
The ClinicalTrials.gov registry entry for NCT03122691 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cannabis is the first listed.
NCT03122691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122691 about?
NCT03122691 is a clinical study titled "Differences in Cannabis Impairment and Its Measurement Due to Route of Administration". This research is being done to measure the effects of both oral and vaporized cannabis (marijuana), at different doses, on the ability to perform certain tasks such as balancing, eye tracking, and computerized measures of memory and attention, as well as performance on a novel app (DRUID) that is be...
What is the current status of trial NCT03122691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-05-01. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT03122691?
The interventions under investigation include: cannabis (DRUG).
Who is sponsoring clinical trial NCT03122691?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.